Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy

INTRODUCTION: Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy. However, its role in patients with mPAC previously treated with conventional i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Kyunghye, Cheon, Jaekyung, Jeong, Jae Ho, Im, Hyeon-Su, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Yoo, Changhoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983461/
https://www.ncbi.nlm.nih.gov/pubmed/33796153
http://dx.doi.org/10.1177/17588359211003053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983461/
https://www.ncbi.nlm.nih.gov/pubmed/33796153
http://dx.doi.org/10.1177/17588359211003053

Ejemplares similares